<DOC>
	<DOCNO>NCT02031458</DOCNO>
	<brief_summary>This multicenter , single-arm study evaluate efficacy safety Atezolizumab participants PD-L1-positive locally advanced metastatic non-small cell lung cancer ( NSCLC ) . Participants receive Atezolizumab 1200 milligram ( mg ) intravenously every 3 week long participant experience clinical benefit assess investigator , , absence unacceptable toxicity symptomatic deterioration attribute disease progression .</brief_summary>
	<brief_title>A Study Atezolizumab Participants With Programmed Death - Ligand 1 ( PD-L1 ) Positive Locally Advanced Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adult participant great equal 18 year age Locally advanced metastatic ( Stage IIIB , Stage IV , recurrent ) NSCLC Representative formalinfixed paraffinembedded ( FFPE ) tumor specimen PDL1positive tumor status determine immunohistochemistry ( IHC ) assay base PDL1 expression tumor infiltrate immune cell and/or tumor cell perform central laboratory Measurable disease , define RECIST version 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Any approve anticancer therapy , include chemotherapy , hormonal therapy within 3 week prior initiation study treatment ; follow exception allow : Hormonereplacement therapy oral contraceptive tyrosinekinase inhibitor ( TKIs ) approve treatment NSCLC discontinue &gt; 7 day prior Cycle 1 , Day 1 Central nervous system ( CNS ) disease , include treat brain metastasis Malignancies NSCLC within 5 year prior randomization , exception negligible risk metastasis death treat expect curative outcome History autoimmune disease History idiopathic pulmonary fibrosis ( include pneumonia ) , druginduced pneumonitis , organize pneumonia , evidence active pneumonitis screen CT scan . History radiation pneumonitis radiation field ( fibrosis ) id permit Active hepatitis B hepatitis C Human Immunodeficiency virus ( HIV ) positive Prior treatment CD137 agonist , antiCTLA4 , antiPD1 , antiPDL1 therapeutic antibody pathwaytargeting agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>